Atomistic subsemirings of the lattice of subspaces of an algebra

Let A be an associative algebra with identity over a field k. An atomistic subsemiring R of the lattice of subspaces of A, endowed with the natural product, is a subsemiring which is a closed atomistic sublattice. When R has no zero divisors, the set of atoms of R is endowed with a multivalued product. We introduce an equivalence relation on the set of atoms such that the quotient set with the induced product is a monoid, called the condensation monoid. Under suitable hypotheses on R, we show that this monoid is a group and the class of k1_A is the set of atoms of a subalgebra of A called the focal subalgebra. This construction can be iterated to obtain higher condensation groups and focal subalgebras. We apply these results to G-algebras for G a group; in particular, we use them to define new invariants for finite-dimensional irreducible projective representations.Comment: 14 page

Proceedings of the third French-Ukrainian workshop on the instrumentation developments for HEP

The reports collected in these proceedings have been presented in the third French-Ukrainian workshop on the instrumentation developments for high-energy physics held at LAL, Orsay on October 15-16. The workshop was conducted in the scope of the IDEATE International Associated Laboratory (LIA). Joint developments between French and Ukrainian laboratories and universities as well as new proposals have been discussed. The main topics of the papers presented in the Proceedings are developments for accelerator and beam monitoring, detector developments, joint developments for large-scale high-energy and astroparticle physics projects, medical applications.Comment: 3rd French-Ukrainian workshop on the instrumentation developments for High Energy Physics, October 15-16, 2015, LAL, Orsay, France, 94 page

Poor outcome in hypoxic endometrial carcinoma is related to vascular density

Background Identification of endometrial carcinoma (EC) patients at high risk of recurrence is lacking. In this study, the prognostic role of hypoxia and angiogenesis was investigated in EC patients. Methods Tumour slides from EC patients were stained by immunofluorescence for carbonic anhydrase IX (CAIX) as hypoxic marker and CD34 for assessment of microvessel density (MVD). CAIX expression was determined in epithelial tumour cells, with a cut-off of 1%. MVD was assessed according to the Weidner method. Correlations with disease-specific survival (DSS), disease-free survival (DFS) and distant disease-free survival (DDFS) were calculated using Kaplan–Meier curves and Cox regression analysis. Results Sixty-three (16.4%) of 385 ECs showed positive CAIX expression with high vascular density. These ECs had a reduced DSS compared to tumours with either hypoxia or high vascular density (log-rank p = 0.002). Multivariable analysis showed that hypoxic tumours with high vascular density had a reduced DSS (hazard ratio [HR] 3.71, p = 0.002), DDFS (HR 2.68, p = 0.009) and a trend for reduced DFS (HR 1.87, p = 0.054). Conclusions This study has shown that adverse outcome in hypoxic ECs is seen in the presence of high vascular density, suggesting an important role of angiogenesis in the metastatic process of hypoxic EC. Differential adjuvant treatment might be indicated for these patients.publishedVersio

Purification of molybdenum oxide, growth and characterization of medium size zinc molybdate crystals for the LUMINEU program

The LUMINEU program aims at performing a pilot experiment on neutrinoless double beta decay of 100Mo using radiopure ZnMoO4 crystals operated as scintillating bolometers. Growth of high quality radiopure crystals is a complex task, since there are no commercially available molybdenum compounds with the required levels of purity and radioactive contamination. This paper discusses approaches to purify molybdenum and synthesize compound for high quality radiopure ZnMoO4 crystal growth. A combination of a double sublimation (with addition of zinc molybdate) with subsequent recrystallization in aqueous solutions (using zinc molybdate as a collector) was used. Zinc molybdate crystals up to 1.5 kg were grown by the low-thermal-gradient Czochralski technique, their optical, luminescent, diamagnetic, thermal and bolometric properties were tested.Comment: Contribution to Proc. of Int. Workshop on Radiopure Scintillators RPSCINT 2013, 17-20 September 2013, Kyiv, Ukraine; to be published in EPJ Web of Conferences; expected to be online in January 2014; 6 pages, 6 figures, and 3 table

Development of 100^{100}Mo-containing scintillating bolometers for a high-sensitivity neutrinoless double-beta decay search

We report recent achievements in the development of scintillating bolometers to search for neutrinoless double-beta decay of $^{100}$Mo. The presented results have been obtained in the framework of the LUMINEU, LUCIFER and EDELWEISS collaborations, and are now part of the R\&D activities towards CUPID (CUORE Update with Particle IDentification), a proposed next-generation double-beta decay experiment based on the CUORE experience. We have developed a technology for the production of large mass ($\sim$1 kg), high optical quality, radiopure zinc and lithium molybdate crystal scintillators (ZnMoO$_4$ and Li$_2$MoO$_4$, respectively) from deeply purified natural and $^{100}$Mo-enriched molybdenum. The procedure is applied for a routine production of enriched crystals. Furthermore, the technology of a single detector module consisting of a large-volume ($\sim 100$~cm$^3$) Zn$^{100}$MoO$_4$ and Li$_2$$^{100}$MoO$_4$ scintillating bolometer has been established, demonstrating performance and radiopurity that are close to satisfy the demands of CUPID. In particular, the FWHM energy resolution of the detectors at 2615 keV --- near the $Q$-value of the double-beta transition of $^{100}$Mo (3034~keV) --- is $\approx$ 4--10~keV. The achieved rejection of $\alpha$-induced dominant background above 2.6~MeV is at the level of more than 99.9\%. The bulk activity of $^{232}$Th ($^{228}$Th) and $^{226}$Ra in the crystals is below 10 $\mu$Bq/kg. Both crystallization and detector technologies favor Li$_2$MoO$_4$, which was selected as a main element for the realization of a CUPID demonstrator (CUPID-0/Mo) with $\sim$7 kg of $^{100}$Mo

Scintillating bolometers based on ZnMoO4 and Zn100MoO4 crystals to search for 0ν2β decay of 100Mo (LUMINEU project): first tests at the Modane Underground Laboratory

The technology of scintillating bolometers based on zinc molybdate (ZnMoO4) crystals is under development within the LUMINEU project to search for decay of 100Mo with the goal to set the basis for large scale experiments capable to explore the inverted hierarchy region of the neutrino mass pattern. Advanced ZnMoO4 crystal scintillators with mass of ∼0.3 kg were developed and Zn100MoO4 crystal from enriched 100Mo was produced for the first time by using the low-thermal-gradient Czochralski technique. One ZnMoO4 scintillator and two samples (59 g and 63 g) cut from the enriched boule were tested aboveground at milli-Kelvin temperature as scintillating bolometers showing a high detection performance. The first results of the low background measurements with three ZnMoO4 and two enriched detectors installed in the EDELWEISS set-up at the Modane Underground Laboratory (France) are presented

Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study

Background: Bayesian networks (BNs) are machine-learning-based computational models that visualize causal relationships and provide insight into the processes underlying disease progression, closely resembling clinical decision-making. Preoperative identification of patients at risk for lymph node metastasis (LNM) is challenging in endometrial cancer, and although several biomarkers are related to LNM, none of them are incorporated in clinical practice. The aim of this study was to develop and externally validate a preoperative BN to predict LNM and outcome in endometrial cancer patients.Methods and findings: Within the European Network for Individualized Treatment of Endometrial Cancer (ENI-TEC), we performed a retrospective multicenter cohort study including 763 patients, median age 65 years (interquartile range [IQR] 58-71), surgically treated for endometrial cancer between February 1995 and August 2013 at one of the 10 participating European hospitals. A BN was developed using score-based machine learning in addition to expert knowledge. Our main outcome measures were LNM and 5-year disease-specific survival (DSS). Preoperative clinical, histopathological, and molecular biomarkers were included in the network. External validation was performed using 2 prospective study cohorts: the Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC) study cohort, including 446 Norwegian patients, median age 64 years (IQR 59-74), treated between May 2001 and 2010; and the PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study cohort, including 384 Dutch patients, median age 66 years (IQR 60-73), treated between September 2011 and December 2013. A BN called ENDORISK (preoperative risk stratification in endometrial cancer) was developed including the following predictors: preoperative tumor grade; immunohistochemical expression of estrogen receptor (ER), progesterone receptor (PR), p53, and L1 cell adhesion molecule (L1CAM); cancer antigen 125 serum level; thrombocyte count; imaging results on lymphadenopathy; and cervical cytology. In the MoMaTEC cohort, the area under the curve (AUC) was 0.82 (95% confidence interval [CI] 0.76-0.88) for LNM and 0.82 (95% CI 0.77-0.87) for 5-year DSS. In the PIPENDO cohort, the AUC for 5-year DSS was 0.84 (95% CI 0.78-0.90). The network was well-calibrated. In the MoMaTEC cohort, 249 patients (55.8%) were classified with Conclusions: In this study, we illustrated how BNs can be used for individualizing clinical decision-making in oncology by incorporating easily accessible and multimodal biomarkers. The network shows the complex interactions underlying the carcinogenetic process of endometrial cancer by its graphical representation. A prospective feasibility study will be needed prior to implementation in the clinic.</div